Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Kyprolis is a prescription proteasome inhibitor containing carfilzomib. It is used in adults with relapsed or refractory multiple myeloma after prior treatment, either alone or with selected combination regimens.
read more about kyprolis ...Carfilzomib binds irreversibly to the proteolytic core of the 20S proteasome and inhibits proteasome activity. This disrupts protein breakdown inside susceptible cancer cells and can lead to cell death.
Kyprolis is used in adults with relapsed or refractory multiple myeloma who have received one to three prior treatment lines when used with selected combination regimens. It is also used alone after one or more prior treatment lines.
Kyprolis is given by intravenous infusion in 28-day cycles. A common once-weekly regimen starts at 20 mg per square meter on cycle 1 day 1 and increases to 70 mg per square meter on days 8 and 15 if tolerated. Other labeled regimens use 20 mg per square meter followed by 56 mg or 27 mg per square meter twice weekly, depending on the treatment combination.
Serious concerns include cardiac failure and ischemia, acute kidney failure, tumor lysis syndrome, pulmonary toxicity, pulmonary hypertension, severe high blood pressure, venous thrombosis, infusion reactions, hemorrhage, thrombocytopenia, liver toxicity, thrombotic microangiopathy, posterior reversible encephalopathy syndrome, and progressive multifocal leukoencephalopathy.
Kyprolis treats relapsed or refractory multiple myeloma in adults under prior-treatment criteria.
Kyprolis is given by intravenous infusion.
Yes. Current labeling includes once-weekly and twice-weekly regimens that vary by accompanying medicines.
Hydration is used around early treatment to reduce risks associated with tumor lysis syndrome and kidney toxicity, with adjustments for patients at risk of fluid overload.
Carfilzomib. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/carfilzomib. Date Accessed October 8, 2026.
Carfilzomib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Carfilzomib. Date Accessed October 8, 2026.
Carfilzomib Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a612031.html. Date Accessed October 8, 2026.
DailyMed - KYPROLIS (carfilzomib) injection, powder, lyophilized, for solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6. Date Accessed October 8, 2026.
KYPROLIS (carfilzomib) Prescribing Information. Amgen. https://www.pi.amgen.com/united_states/kyprolis/kyprolis_pi.pdf. Date Accessed October 8, 2026.